NIKKEI 225
38,799.95 -146.98 (-0.38%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,425.50 -0.40 (-0.02%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
55,177.93 -918.48 (-1.64%)
LLY Jun 2024 360.000 call
| Previous close | 396.75 |
| Open | 445.79 |
| Bid | 441.25 |
| Ask | 449.90 |
| Strike | 360.00 |
| Expiry date | 2024-06-21 |
| Day's range | 445.79 - 445.79 |
| Contract range | N/A |
| Volume | |
| Open interest | 108 |
Investor's Business DailyDow Jones Futures: Nasdaq Hits High, Eli Lilly Breaks Out, But Here Comes Nvidia
Tuesday was a quiet session but the Nasdaq hit a record high while megacaps Eli Lilly and Microsoft flashed buy signals. Nvidia earnings loom large.
Investor's Business DailyIBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High
Eli Lilly is Tuesday's IBD Stock Of The Day after shares surged into a buy zone, again, on promising test results for a Crohn's treatment.
PR NewswireMore than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure
In Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically significant and clinically meaningful improvements across multiple clinical and endoscopic endpoints at one year with mirikizumab compared to placebo. Data from this study – the first Phase 3 treat-through data reported for an IL23p19 antibody – will be presented at Digestive Disease Week® (DDW), held
